Top

International Journal of Diabetes in Developing Countries

13-11-2024 | Chronic Heart Failure | Original Article

Predictive value of aberrant serum miR-1224 in diabetes mellitus with chronic heart failure patients

Authors: Chenxing Ma, Zhaoxiang Wang

Published in: International Journal of Diabetes in Developing Countries

Abstract

Background

Heart failure (HF) is one of the most common complications of type 2 diabetes mellitus (T2DM). The significant morbidity and mortality associated with the combination of T2DM and HF have increasingly drawn clinical attention.

Objective

To investigate the expression of miR-1224 in T2DM patients with chronic heart failure (CHF). The diagnostic value of miR-1224 in T2DM patients with CHF was further evaluated.

Methods

A total of 95 T2DM patients and 95 T2DM patients with CHF were enrolled in this study. RT-qPCR was used to detect the expression level of miR-1224 in the serum of patients in the two groups. ROC curve was drawn to evaluate the diagnostic value of miR-1224 in the two groups of patients. Binary logistic regression was used to analyze the effect of miR-1224 and other factors on the rehospitalization rate of T2DM patients with CHF.

Results

The serum miR-1224 expression level was significantly higher in T2DM patients with CHF than in those without CHF. As the NYHA classification increased, so did the expression level of miR-1224. The miR-1224 could diagnose T2DM combined with CHF and was a factor influencing rehospitalization in T2DM and CHF patients.

Conclusion

The study suggests a correlation between miR-1224 and cardiac function, as well as the diagnosis and rehospitalization rates of T2DM patients with CHF. It proposes that miR-1224 could serve as a new biomarker for diagnosing T2DM with CHF.

Maack C, Lehrke M, Backs J, Heinzel FR, Hulot JS, Marx N, et al. Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. Eur Heart J. 2018;39(48):4243–54. https://doi.org/10.1186/s13019-022-01802-0.CrossRefPubMedPubMedCentral

Bozkurt B, Coats A, Tsutsui H. Universal definition and classification of heart failure. J Cardiac Fail. 2021. https://doi.org/10.1016/j.cardfail.2021.01.022.CrossRef

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726. https://doi.org/10.1093/eurheartj/ehab368.CrossRefPubMed

Blumer V, Mentz RJ, Sun JL, Butler J, Metra M, Voors AA, et al. Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure. Circ Heart Fail. 2021;14(4):e007871. https://doi.org/10.1161/circheartfailure.120.007871.CrossRefPubMedPubMedCentral

Toi PL, Anothaisintawee T, Chaikledkaew U, Briones JR, Reutrakul S, Thakkinstian A. Preventive role of diet interventions and dietary factors in type 2 diabetes mellitus: An umbrella review. Nutrients. 2020;12(9). https://doi.org/10.3390/nu1209272.

Dick SA, Epelman S. Chronic heart failure and inflammation: What do we really know? Circ Res. 2016;119(1):159–76. https://doi.org/10.1161/circresaha.116.308030.CrossRefPubMed

Romero A, Saldarriaga C, Ramos CE, Quesada D, Chazzin G, Fernández FN, et al. Consensus document of the management of type 2 diabetes and heart failure: Consejo Interamericano de Falla Cardíaca e Hipertensión Pulmonar (CIFACAH) and Inter-American Society of Cardiology (IASC). Archivos de cardiologia de Mexico. 2023;93(Supl):14–26. https://doi.org/10.24875/acm.23000059.CrossRefPubMedPubMedCentral

Chong VH, Singh J, Parry H, Saunders J, Chowdhury F, Mancini DM, et al. Management of Noncardiac Comorbidities in Chronic Heart Failure. Cardiovasc Ther. 2015;33(5):300–15. https://doi.org/10.1111/1755-5922.12141.CrossRefPubMed

Milinković I, Polovina M, Seferović PM. Age old problem: heart failure treatment in elderly. Eur J Prev Cardiol. 2019;26(13):1396–8. https://doi.org/10.1177/2047487319853643.CrossRefPubMed

10.

Banerjee M, Maisnam I, Mukhopadhyay S. Impact of heart failure history at baseline on cardiovascular effects of GLP-1 receptor agonists in Type 2 diabetes: a Meta-analysis. Cardiovasc Drugs Ther. 2023. https://doi.org/10.1007/s10557-023-07432-5.CrossRefPubMed

11.

Muñoz-Rivas N, Jiménez-García R, Méndez-Bailón M, Hernández-Barrera V, de Miguel-Díez J, Lorenzo-Villalba N, et al. Type 2 diabetes increases the risk of hospital admission for heart failure and reduces the risk of in hospital mortality in Spain (2001–2015). Eur J Intern Med. 2019;59:53–9. https://doi.org/10.1016/j.ejim.2018.08.011.CrossRefPubMed

12.

Zhao S, Wang H, Xu H, Tan Y, Zhang C, Zeng Q, et al. Targeting the microRNAs in exosome: A potential therapeutic strategy for alleviation of diabetes-related cardiovascular complication. Pharmacol Res. 2021;173:105868. https://doi.org/10.1016/j.phrs.2021.105868.CrossRefPubMed

13.

Su X, Yang X, Liu H. Long Non-coding RNA SPAG5-AS1 attenuates diabetic retinal vascular dysfunction by inhibiting human retinal microvascular endothelial cell proliferation, migration, and tube formation by regulating the MicroRNA-1224-5p/IRS-1 Axis. Mol Biotechnol. 2023;65(6):904–12. https://doi.org/10.1007/s12033-022-00572-3.CrossRefPubMed

14.

Li G, Jin J, Liu S, Ding K, Qian C. Inhibition of miR-1224 suppresses hypoxia/reoxygenation-induced oxidative stress and apoptosis in cardiomyocytes through targeting GPX4. Exp Mol Pathol. 2021;121:104645. https://doi.org/10.1016/j.yexmp.2021.104645.CrossRefPubMed

15.

Ghafouri-Fard S, Askari A, Behzad Moghadam K, Hussen BM, Taheri M, Samadian M. A review on the role of ZEB1-AS1 in human disorders. Pathol Res Pract. 2023;245:154486. https://doi.org/10.1016/j.prp.2023.154486.CrossRefPubMed

16.

Burggraaf B, Castro CM. Interventions in type 2 diabetes mellitus and cardiovascular mortality-An overview of clinical trials. Eur J Intern Med. 2017;42:1–15. https://doi.org/10.1016/j.ejim.2017.04.017.CrossRefPubMed

17.

Li W, Lv XZ, Liu J, Zeng JH, Ye M, Li CL, et al. Assessment of myocardial dysfunction by three-dimensional echocardiography combined with myocardial contrast echocardiography in Type 2 diabetes mellitus. Front Cardiovasc Med. 2021;8:677990. https://doi.org/10.3389/fcvm.2021.677990.CrossRefPubMedPubMedCentral

18.

Baumhove L, Tromp J, Figarska S, van Essen BJ, Anker SD, Dickstein K, et al. Heart failure with normal LVEF in BIOSTAT-CHF. Int J Cardiol. 2022;364:85–90. https://doi.org/10.1016/j.ijcard.2022.05.054.CrossRefPubMed

19.

De Geer L, Fredrikson M, Oscarsson A. Amino-terminal pro-brain natriuretic peptide as a predictor of outcome in patients admitted to intensive care. A prospective observational study. Eur J Anaesthesiol. 2012;29(6):275–9. https://doi.org/10.1097/EJA.0b013e32835470a8.CrossRefPubMed

20.

Kim SE, Cho DH, Son JW, Kim JY, Kang SM, Cho MC, et al. Impact of NT-proBNP on prognosis of acute decompensated chronic heart failure versus de novo heart failure. Int J Cardiol. 2022;363:163–70. https://doi.org/10.1016/j.ijcard.2022.06.055.CrossRefPubMed

21.

Cruz MS, da Silva AMG, de Souza KSC, Luchessi AD, Silbiger VN. miRNAs emerge as circulating biomarkers of post-myocardial infarction heart failure. Heart Fail Rev. 2020;25(2):321–9. https://doi.org/10.1007/s10741-019-09821-1.CrossRefPubMed

22.

Qian L, Zhao Q, Yu P, Lü J, Guo Y, Gong X, et al. Diagnostic potential of a circulating miRNA model associated with therapeutic effect in heart failure. J Transl Med. 2022;20(1):267. https://doi.org/10.1186/s12967-022-03465-w.CrossRefPubMedPubMedCentral

23.

Han Q, Zhang L, Liao R. Diagnostic and prognostic significance of miR-320a-3p in patients with chronic heart failure. BMC Cardiovasc Disord. 2024;24(1):308. https://doi.org/10.1186/s12872-024-03966-0.CrossRefPubMedPubMedCentral

24.

Luo Y, Deng X, Chen Q, Cai Y, Bie M, Zhang Y, et al. Up-regulation of miR-155 protects against chronic heart failure by inhibiting HIF-1α. Am J Transl Res. 2023;15(11):6425–36.PubMedPubMedCentral

25.

Roy S, Bantel H, Wandrer F, Schneider AT, Gautheron J, Vucur M, et al. miR-1224 inhibits cell proliferation in acute liver failure by targeting the antiapoptotic gene Nfib. J Hepatol. 2017;67(5):966–78. https://doi.org/10.1016/j.jhep.2017.06.007.CrossRefPubMed

26.

Bielska A, Niemira M, Bauer W, Sidorkiewicz I, Szałkowska A, Skwarska A, et al. Serum miRNA Profile in Diabetic Patients With Ischemic Heart Disease as a Promising Non-Invasive Biomarker. Front Endocrinol. 2022;13:888948. https://doi.org/10.3389/fendo.2022.888948.CrossRef

27.

Tromp J, Tay WT, Ouwerkerk W, Teng TK, Yap J, MacDonald MR, et al. Correction: Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry. PLoS Med. 2018;15(5):e1002583. https://doi.org/10.1371/journal.pmed.1002583.CrossRefPubMedPubMedCentral

28.

Tromp J, Tay WT, Ouwerkerk W, Teng TK, Yap J, MacDonald MR, et al. Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry. PLoS Med. 2018;15(3):e1002541. https://doi.org/10.1371/journal.pmed.1002541.CrossRefPubMedPubMedCentral

29.

Fang F, Zhang X, Li B, Gan S. miR-182-5p combined with brain-derived neurotrophic factor assists the diagnosis of chronic heart failure and predicts a poor prognosis. J Cardiothorac Surg. 2022;17(1):88. https://doi.org/10.1186/s13019-022-01802-0.CrossRefPubMedPubMedCentral

30.

Zang F, Wei X, Leng X, Yu M, Sun B. C-FLIP(L) contributes to TRAIL resistance in HER2-positive breast cancer. Biochem Biophys Res Commun. 2014;450(1):267–73. https://doi.org/10.1016/j.bbrc.2014.05.106.CrossRefPubMed

31.

Imai H, Matsuoka M, Kumagai T, Sakamoto T, Koumura T. Lipid peroxidation-dependent cell death regulated by GPx4 and Ferroptosis. Curr Top Microbiol Immunol. 2017;403:143–70. https://doi.org/10.1007/82_2016_508.CrossRefPubMed

32.

Wang EW, Jia XS, Ruan CW, Ge ZR. miR-487b mitigates chronic heart failure through inhibition of the IL-33/ST2 signaling pathway. Oncotarget. 2017;8(31):51688–702. https://doi.org/10.18632/oncotarget.18393.CrossRefPubMedPubMedCentral

33.

Pan J, Wang X, Cang X, Jiang Y, Tang R. Hsa_circ_0010957 knockdown attenuates lipopolysaccharide-induced HK2 cell injury by regulating the miR-1224-5p/IRAK1 axis. Central-Eur J Immunol. 2021;46(3):314–24. https://doi.org/10.5114/ceji.2021.108772.CrossRef

Title: Predictive value of aberrant serum miR-1224 in diabetes mellitus with chronic heart failure patients
Authors: Chenxing Ma
Zhaoxiang Wang
Publication date: 13-11-2024
Publisher: Springer India
Keywords: Chronic Heart Failure
Heart Failure
Type 2 Diabetes
Published in: International Journal of Diabetes in Developing Countries
Print ISSN: 0973-3930
Electronic ISSN: 1998-3832
DOI: https://doi.org/10.1007/s13410-024-01424-3

Elevate your expertise in aplastic anemia (Link opens in a new window)

Aplastic Anemia
Independent Medical Education

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases.

Supported by:

Pfizer

Developed by: Springer Healthcare IME

Learn more

Keynote series | Spotlight on menopause

Menopause
Video Series

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Prof. Martha Hickey

Dr. Claudia Barth

Dr. Samar El Khoudary

Developed by: Springer Medicine

Watch now